There’s a new class of weight-loss drugs in town. GLP-1 medications including Ozempic, Wegovy and Mounjaro were created to treat diabetes, but have since been found to suppress appetites and induce substantial weight loss. It’s a big deal for the companies which make them, with shares of Novo Nordisk and Eli Lilly soaring in recent weeks. But the drugs could end up having a much broader economic impact too. On this episode, we speak with James van Geelen of Citrinitas Capital, about the second-order effects of widely available, effective weight-loss drugs. He talks us through how he’s evaluating the potential of the new meds and how he approaches possible ‘mega-trends’ like GLP-1 or AI.